Symmetry Investments’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Symmetry Investments’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$1.19M	–	145
2022 Q1	$1.19M	Buy	+10,000	New	+$1.25M	0.17%	70
2021 Q4	–	Sell	-6,600	Closed	-$917K	–	161
2021 Q3	$917K	Sell	6,600 -9,400	-59%	-$1.17M	0.14%	99
2021 Q2	$1.55M	Sell	16,000 -29,001	-64%	-$2.35M	0.44%	50
2021 Q1	$3.08M	Buy	+45,001	New	+$3.64M	0.74%	38

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Symmetry Investments's BHVN Position: Q2 2022 in Review

Symmetry Investments sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 10,000 shares — an estimated $1.19M sold.

Symmetry Investments first reported a position in BHVN in Q1 2021 and held it in 4 quarters. The position peaked at $3.08M in Q1 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Symmetry Investments reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Symmetry Investments sold 10,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $1.19M.
Symmetry Investments first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 4 quarters.
Symmetry Investments's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.08M in Q1 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Symmetry Investments's 13F filing for Q2 2022, filed 26 Jul 2022.